MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.90
+0.59
+1.27%
Pre Market: 47.38 +0.48 +1.02% 08:50 11/22 EST
OPEN
46.44
PREV CLOSE
46.31
HIGH
46.95
LOW
45.68
VOLUME
390.34K
TURNOVER
--
52 WEEK HIGH
64.48
52 WEEK LOW
35.04
MARKET CAP
2.35B
P/E (TTM)
4.346
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARNA News

  • California Life Sciences Association Honors Arena Pharmaceuticals at the Pantheon 2019 DiNA™ Awards for the Deal of the Year
  • PR Newswire.3d ago
  • Week In Review: BeiGene's BTK Inhibitor Approved In U.S., And China Approval For PD-1 Expected In 2 Months
  • Seeking Alpha - Article.4d ago
  • Edited Transcript of ARNA earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.5d ago
  • Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia
  • GlobeNewswire.11/14 14:00

More

Industry

Biotechnology & Medical Research
-0.13%
Pharmaceuticals & Medical Research
+0.43%

Hot Stocks

Name
Price
%Change

About ARNA

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
More

Webull offers Arena Pharmaceuticals, Inc. (ARNA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.